Paolo Bernasconi

Summary

Affiliation: University of Pavia
Country: Italy

Publications

  1. doi request reprint Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution
    Paolo Bernasconi
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Am J Hematol 88:120-9. 2013
  2. ncbi request reprint World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes
    Paolo Bernasconi
    Division of Haematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 137:193-205. 2007
  3. doi request reprint Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review
    Paolo Bernasconi
    Division of Haematology, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 142:695-708. 2008
  4. doi request reprint Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution
    Paolo Bernasconi
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy
    Ann Hematol 89:545-51. 2010
  5. ncbi request reprint Clinical relevance of cytogenetics in myelodysplastic syndromes
    Paolo Bernasconi
    Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Fondazione Policlinico San Matteo IRCCS, Pavia, Italy
    Ann N Y Acad Sci 1089:395-410. 2006
  6. ncbi request reprint ABL1 amplification in T-cell acute lymphoblastic leukemia
    Paolo Bernasconi
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi No 5, 27100 Pavia, Italy
    Cancer Genet Cytogenet 162:146-50. 2005
  7. ncbi request reprint Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution
    P Bernasconi
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Leukemia 19:1424-31. 2005
  8. ncbi request reprint Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance
    Paolo Bernasconi
    Department of Blood, Heart and Lung Medical Sciences, Division of Haematology, Policlinico San Matteo IRCCS, University of Pavia, 27100 Pavia, Italy
    Br J Haematol 118:545-9. 2002
  9. ncbi request reprint Molecular genetics of acute myeloid leukemia
    Paolo Bernasconi
    Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Policlinico San Matteo IRCCS, Pavia, Italy
    Ann N Y Acad Sci 963:297-305. 2002
  10. ncbi request reprint Molecularly targeted therapy in acute myeloid leukemia
    Paolo Bernasconi
    Department of Blood, Heart and Lung Medical Sciences of the University of Pavia, Italy
    Ann N Y Acad Sci 1028:409-22. 2004

Collaborators

Detail Information

Publications28

  1. doi request reprint Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution
    Paolo Bernasconi
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Am J Hematol 88:120-9. 2013
    ....
  2. ncbi request reprint World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes
    Paolo Bernasconi
    Division of Haematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 137:193-205. 2007
    ....
  3. doi request reprint Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review
    Paolo Bernasconi
    Division of Haematology, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 142:695-708. 2008
    ..In early MDS, stromal and neoplastic cells produce high levels of inhibitory cytokines, whereas in advanced MDS and AML they produce high levels of anti-apoptotic molecules...
  4. doi request reprint Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution
    Paolo Bernasconi
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy
    Ann Hematol 89:545-51. 2010
    ....
  5. ncbi request reprint Clinical relevance of cytogenetics in myelodysplastic syndromes
    Paolo Bernasconi
    Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Fondazione Policlinico San Matteo IRCCS, Pavia, Italy
    Ann N Y Acad Sci 1089:395-410. 2006
    ..In addition, chromosome abnormalities are independent prognostic factors predicting overall survival and the likelihood of progression in acute myeloid leukemia...
  6. ncbi request reprint ABL1 amplification in T-cell acute lymphoblastic leukemia
    Paolo Bernasconi
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi No 5, 27100 Pavia, Italy
    Cancer Genet Cytogenet 162:146-50. 2005
    ....
  7. ncbi request reprint Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution
    P Bernasconi
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Leukemia 19:1424-31. 2005
    ....
  8. ncbi request reprint Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance
    Paolo Bernasconi
    Department of Blood, Heart and Lung Medical Sciences, Division of Haematology, Policlinico San Matteo IRCCS, University of Pavia, 27100 Pavia, Italy
    Br J Haematol 118:545-9. 2002
    ..3;q32) remains to be demonstrated. However, a transition from MGUS to MM may also occur in patients with normal karyotypes or other abnormalities, suggesting the possibility of distinct pathogenetic pathways...
  9. ncbi request reprint Molecular genetics of acute myeloid leukemia
    Paolo Bernasconi
    Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Policlinico San Matteo IRCCS, Pavia, Italy
    Ann N Y Acad Sci 963:297-305. 2002
    ..Understanding the action of such genes provides new insights into AML pathogenesis and has led us to envisage new therapeutic options...
  10. ncbi request reprint Molecularly targeted therapy in acute myeloid leukemia
    Paolo Bernasconi
    Department of Blood, Heart and Lung Medical Sciences of the University of Pavia, Italy
    Ann N Y Acad Sci 1028:409-22. 2004
    ..All these new data have profound clinical and therapeutic implications and will surely translate into the development of molecules that target specific mutations or signal transduction pathways...
  11. doi request reprint Blast phase of essential thrombocythemia: A single center study
    Francesco Passamonti
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Am J Hematol 84:641-4. 2009
    ..JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia. The outcome of patients is poor whatever the treatment used...
  12. ncbi request reprint Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase-FISH
    Ester M Orlandi
    Department of Oncology Hematology, Hematology Unit Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Hematol Oncol 31:136-42. 2013
    ..001). The appearance of a new clone was detected in 16 patients (15.5%) and chromosome 13 was involved in 14 of them. I-FISH monitoring proves worthwhile for a dynamic risk stratification and for planning clinical surveillance...
  13. doi request reprint Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
    Francesco Passamonti
    M D, Division of Hematology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Haematologica 93:1645-51. 2008
    ..Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this disorder have a propensity to develop thrombosis, myelofibrosis, and leukemia...
  14. ncbi request reprint Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
    Luca Malcovati
    Department of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy
    J Clin Oncol 25:3503-10. 2007
    ....
  15. doi request reprint Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome
    Irene Dambruoso
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
    Cancer Genet 205:285-94. 2012
    ....
  16. ncbi request reprint Role of the molecular staging and response in the management of follicular lymphoma patients
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy
    Leuk Lymphoma 47:1018-22. 2006
    ..Absence of the bcl-2 rearrangement is related to a better EFS and the achievement of a molecular response in peripheral blood after therapy is associated with a better EFS...
  17. ncbi request reprint Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
    Luca Malcovati
    Division of Hematology, IRCCS, Policlinico San Matteo, 27100 Pavia, Italy
    J Clin Oncol 23:7594-603. 2005
    ....
  18. ncbi request reprint Leukemic transformation of polycythemia vera: a single center study of 23 patients
    Francesco Passamonti
    Division of Hematology, IRCCS San Matteo Polyclinic, University of Pavia, Pavia, Italy
    Cancer 104:1032-6. 2005
    ..Acute leukemia (AL) may occur as rare and late event of polycythemia vera (PV)...
  19. doi request reprint Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma
    Alessandro Corso
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Leuk Lymphoma 51:236-42. 2010
    ..In conclusion, Vel-Dex produces high response rates, improves stem cell collection, and overcomes the need for intensification before autologous transplantation...
  20. ncbi request reprint Survivin expression in acute leukemias and myelodysplastic syndromes
    Rosangela Invernizzi
    Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S Matteo, Pavia, Italy
    Leuk Lymphoma 45:2229-37. 2004
    ..Its abnormal expression also in MDS may play a role in promoting aberrantly increased cell viability and contribute to the altered homeostatic balance between cell growth and cell death...
  21. doi request reprint A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
    Francesco Passamonti
    Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Italy
    Blood 111:3383-7. 2008
    ..In conclusion, leukocytosis at diagnosis of PV is a risk factor for evolution in post-PV MF. A dynamic score based on hemoglobin level, and platelet and leukocyte count predicts survival at any time from diagnosis of post-PV MF...
  22. ncbi request reprint Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
    Matteo G Della Porta
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
    Blood 123:2333-42. 2014
    ..In addition, it reinforces the concept that allogeneic HSCT offers optimal eradication of myelodysplastic hematopoiesis when the procedure is performed before MDS patients progress to advanced disease stages...
  23. ncbi request reprint Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications
    Claudia Del Fante
    Immuno hematology and Transfusion Service, Apheresis and Cell Therapy Unit, and Scientific Direction and Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Transfusion 52:2007-15. 2012
    ..Chronic graft-versus-host disease (cGVHD) classification has recently been improved by the National Institutes of Health (NIH); patients' stratification with those new criteria has implications for patients' prognosis...
  24. ncbi request reprint Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma
    Mario Lazzarino
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Oncology 68:146-53. 2005
    ..Because of the different mechanisms of action and non-overlapping toxicities, combination of rituximab with chemotherapy is a rational approach...
  25. ncbi request reprint A further case of myeloproliferative syndrome with reciprocal translocation (8;13)(p11;q12)
    Rosangela Invernizzi
    Medicina Interna ed Oncologia Medica, Universita di Pavia, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 89:239-41. 2004
  26. pmc High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis
    Vittorio Rosti
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Pavia, Italy
    PLoS ONE 5:e15277. 2010
    ..Due to inherent performance limitations of ECFCs assay, there is an urgent need to arrive to an acceptable standardization of ECFC assessment...
  27. ncbi request reprint Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease
    Anna A Colombo
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Transplantation 81:1087-92. 2006
    ..This study aims to determine the incidence and outcome of nephrotic syndrome in patients who underwent allogeneic stem cell transplantation in a single center...
  28. ncbi request reprint Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis
    Francesco Passamonti
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 116:855-61. 2002
    ..The low cumulative 10-year risk of thrombosis, leukaemia and solid tumours indicates that pipobroman is an adequate treatment for patients with high risk ET...